Business
Novo Nordisk and Eli Lilly have been battling head-to-head in an exploding obesity market. They should never have been compared apples to apples.
FEATURED STORIES
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to grow its drug manufacturing sector.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The U.S. Department of Justice has leveled more charges against members of the U.S. science community who have alleged ties to China.
GeoVax Labs, Inc., a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, together with BravoVax, a vaccine developer in Wuhan, China, today announced the signing of a Letter of Intent to jointly develop a vaccine against the new coronavirus.
In the complaint, the FTC alleged an “elaborate anticompetitive scheme to preserve a monopoly” on Daraprim.
Bionetix, ProQinase and MercachemSyncom announced they have signed a joint multiyear integrated drug-discovery project, starting from target identification up to clinical candidate selection on an undisclosed target aimed at acute myeloid leukemia.
Partnership plans molecular biological characterisation of up to 8000 clinically relevant isolates of pathogens resistant to multiple antibiotics using the latest sequencing technology.
QuantuMDx Group Limited announces a business update and the appointments of Jonathan O’Halloran as Chief Executive Officer and Neil Butler as Chairman of the Board, as the company begins its transition to commercialisation..
Evotec SE and Indivumed GmbH announced that the companies have entered into a new research collaboration to discover and develop first-in-class therapeutics for the treatment of non-small cell lung cancer.
Let’s look at a few ways inclusion and diversity positively impact organizational performance.
It was founded in 1982, almost forty years ago, and doesn’t have a commercial product on the market. But that appears likely to soon change.
Global reach extended to major pharma market in Oceania